Innate Pharma S.A. (NASDAQ:IPHA) Q3 2022 Earnings Conference Call November 14, 2022 8:00 AM ET

Company Participants

Henry Wheeler – Head-Investor Relations

Mondher Mahjoubi – Chief Executive Officer

Joyson Karakunnel – Executive Vice President and Chief Medical Officer

Yannis Morel – Executive Vice President-Business Development and Product Portfolio Strategy

Conference Call Participants

Yigal Nochomovitz – Citigroup

Daina Graybosch – SVB Securities

Swayampakula Ramakanth – HCW

Operator

Hello, and thank you for standing by. My name is Regina and I will be your conference operator today. At this time I would like to welcome everyone to the Innate Pharma publication of revenue for Third Quarter 2022 Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks there will be a question-and-answer session. [Operator Instructions]

I would now like to turn the conference over to Henry Wheeler, Head of Investor Relations. Please go ahead.

Henry Wheeler

Thank you. Good morning. Good afternoon. And welcome everyone.

This morning, Innate issued a press release providing a business update for our Q3 2022 results. We look forward to highlighting the progress made during the quarter as well as addressing future goals and milestones. The press release and today's presentation are both available on the IR section of the website.

On Slide 2, before we start, I would like to remind you that we will make forward-looking statements regarding the financial outlook in addition to regulatory and product plan developments. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted.

On Slide 3, on today's call, you will see we will be joined by Mondher Mahjoubi, our Chief Executive Officer; who will then hand over to Joyson Karakunnel, EVP and Chief Medical Officer; and then Yannis Morel, EVP of Business Development and Product Portfolio Strategy. We will also have our CFO, Frederic Lombard, on the line for Q&A.

Mondher, I’ll now hand the call over to you.

Mondher Mahjoubi

Thank you, Henry. Good morning. Good afternoon everyone and thank you for joining our call today.

Please move to Slide 4. And let me start by reminding you our strategy. Our strategy centers around three key priorities where we look to derive value from our early R&D effort through later stage partnerships, where it makes sense to do so. Firstly, we look to create near-term value driven by our lead proprietary product candidate, lacutamab, which is in development for T-cell lymphoma, with readouts in PTCL happening in the second half of this year, and two trials in the larger indication of peripheral T-cell lymphoma underway.